Use of voriconazole to predict susceptibility and resistance to isavuconazole for <i>Aspergillus fumigatus</i> using CLSI methods and interpretive criteria.

ABSTRACT: Aspergillus fumigatus is a common cause of pulmonary and invasive mold infections among immunocompromised hosts. Mortality in immunocompromised hosts with invasive Aspergillus infections (IAI) has been reported to be as high as 80%. Therefore, appropriate therapy is essential in treating IAI. Both isavuconazole and voriconazole are first-line agents in treatment guidelines for IAI, but isavuconazole has favorable properties, often leading it to be preferred over voriconazole, given the lengthy duration of treatment. It is difficult to perform mold antifungal susceptibility testing, which often requires a reference lab and several weeks to determine results. Therefore, use of surrogate markers can be helpful to infer susceptibility when testing is not possible or delayed. We p

SUBMITTER: Winkler ML 

PROVIDER: S-EPMC11837495 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature